1,633 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
AMGN Amgen Inc. $200.81 $129.98B Downtrend
Article Searches
Spectrum (SPPI) Misses Earnings Estimates in Q4, Tops Sales http://www.zacks.com/stock/news/357418/spectrum-sppi-misses-earnings-estimates-in-q4-tops-sales?cid=CS-ZC-FT-357418 Mar 01, 2019 - Spectrum Pharma (SPPI) misses bottom-line estimates in the fourth quarter but beats on revenues.
Stocks making the biggest moves premarket: Home Depot, Caterpillar, Tesla & more https://www.cnbc.com/2019/02/26/stocks-making-the-biggest-moves-premarket-home-depot-caterpillar-tesla--more.html Feb 26, 2019 - Names on the move ahead of the open.
Amgen prevails in PCSK9 patent dispute with Regeneron and Sanofi https://seekingalpha.com/news/3436908-amgen-prevails-pcsk9-patent-dispute-regeneron-sanofi?source=feed_news_all Feb 25, 2019 - A Delaware jury has confirmed the validity of two Amgen (NASDAQ:AMGN) patents covering high cholesterol med Repatha (evolocumab), specifically, the antibodies that bind to a specific region on PCSK9 a
Goldman says the US economy has 'sharply decelerated' but these stocks can still do well https://www.cnbc.com/2019/02/25/goldman-says-the-us-economy-has-sharply-decelerated-but-these-stocks-can-still-do-well.html Feb 25, 2019 - In the face of a slowing economy, companies with low operating leverage should outperform, according to Goldman Sachs.
Roche (RHHBY) to Acquire Spark Therapeutics for $4.8 Billion http://www.zacks.com/stock/news/356763/roche-rhhby-to-acquire-spark-therapeutics-for-%2448-billion?cid=CS-ZC-FT-356763 Feb 25, 2019 - Roche (RHHBY) to acquire Philadelphia-based gene therapy company, Spark Therapeutics, Inc. (ONCE) at a price of $114.50 per share in an all-cash transaction.
Amgen Starts Phase III Enrollment for Heart Failure Drug http://www.zacks.com/stock/news/356653/amgen-starts-phase-iii-enrollment-for-heart-failure-drug?cid=CS-ZC-FT-356653 Feb 22, 2019 - Amgen (AMGN) and partners started enrollment for the second phase III study of omecamtiv mecarbil, which is being developed for the potential treatment of heart failure with reduced ejection fraction.
Putnam Fl Investment Management Co Buys Amgen Inc, CVS Health Corp, Cisco Systems Inc, Sells ... http://www.gurufocus.com/news/821173/putnam-fl-investment-management-co-buys-amgen-inc-cvs-health-corp-cisco-systems-inc-sells-aetna-inc-invesco-qqq-trust-series-1-facebook-inc Feb 22, 2019 - Putnam Fl Investment Management Co Buys Amgen Inc, CVS Health Corp, Cisco Systems Inc, Sells Aetna Inc, Invesco QQQ Trust Series 1, Facebook Inc, Stocks: AMGN,CVS,CSCO,IEFA,DRI,BAC,MAS,PBCT,MDT,XLE,AJG,BH, release date:Feb 22, 2019
The Zacks Analyst Blog Highlights: Walmart, Amgen, Honda, TransCanada and TransUnion http://www.zacks.com/stock/news/355997/the-zacks-analyst-blog-highlights-walmart-amgen-honda-transcanada-and-transunion?cid=CS-ZC-FT-355997 Feb 21, 2019 - The Zacks Analyst Blog Highlights: Walmart, Amgen, Honda, TransCanada and TransUnion
Merck Gets Priority Review for Keytruda in Third-Line SCLC http://www.zacks.com/stock/news/355982/merck-gets-priority-review-for-keytruda-in-third-line-sclc?cid=CS-ZC-FT-355982 Feb 21, 2019 - Merck's (MRK) sBLA looking for approval of Keytruda monotherapy for the third-line treatment of small cell lung cancer, a difficult-to-treat cancer, gets FDA's priority review.
Top Analyst Reports for Walmart, Amgen and Honda http://www.zacks.com/research-daily/215092/top-analyst-reports-for-walmart-amgen-and-honda?cid=CS-ZC-FT-215092 Feb 20, 2019 - Top Analyst Reports for Walmart, Amgen and Honda

Pages: 1234567...164

<Page 2>